This work was performed at the College of Veterinary Medicine, University of Georgia, Athens, GA, the University of Wisconsin, Madison, WI, and Veterinary Medical Specialists, Concord, CA.
Phase I Clinical Trial of Vinorelbine in Tumor-Bearing Cats
Article first published online: 10 MAY 2013
Copyright © 2013 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 27, Issue 4, pages 943–948, July/August 2013
How to Cite
Pierro, J.A., Mallett, C.L. and Saba, C.F. (2013), Phase I Clinical Trial of Vinorelbine in Tumor-Bearing Cats. Journal of Veterinary Internal Medicine, 27: 943–948. doi: 10.1111/jvim.12101
This study was presented in part, in abstract form, at the Veterinary Cancer Society 35th Annual Meeting, Las Vegas, NV, 2012
- Issue published online: 15 JUL 2013
- Article first published online: 10 MAY 2013
- Manuscript Accepted: 2 APR 2013
- Manuscript Revised: 15 FEB 2013
- Manuscript Received: 21 NOV 2012
- University of Georgia Clinical Research committee
Vinorelbine (VRL) has been investigated in dogs, but its use in cats has not been studied.
To determine the maximal tolerated dose (MTD) and dose-limiting toxicity (DLT) of VRL in tumor-bearing cats.
Cats were included in this prospective phase I trial if they had confirmed malignancy, received ≥1 VRL treatment, and had adequate follow-up. Previous treatment was acceptable, but concurrent chemotherapy or radiotherapy was not permitted.
Using a modified phase I design, cats were enrolled in cohorts of 3 at a starting dosage of 9 mg/m2. Cats tolerating the first treatment well were eligible to receive additional VRL treatments at escalating dosages; escalations beyond the perceived MTD were permitted based on individual tolerance. Intended treatment interval was 7 days. Patient histories, physical examinations, and complete blood counts were performed weekly.
Nineteen cats were included. Sixty-one VRL treatments were administered. Median number of treatments was 2 (range, 1–9). Starting dosages were 9–12 mg/m2. Maximal dosage administered was 15.5 mg/m2. The MTD was 11.5 mg/m2. Acute DLTs were neutropenia, vomiting, and nephrotoxicity. Other notable toxicities were weight loss and anemia.
Conclusions and Clinical Importance
Vinorelbine is tolerated in cats at a weekly interval. Recommended starting dosage is 11.5 mg/m2. Neutropenia was transient, lasting <7 days; vomiting was self-limiting in most cases. Although VRL-associated nephrotoxicity has not been reported, potential attribution of this toxicity to VRL must not be discounted. Further investigation of the efficacy of VRL in feline malignancies is warranted.